Published in Ophthalmology on January 01, 2009
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol (2011) 2.07
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) (2011) 2.05
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76
Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol (2013) 1.61
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol (2014) 1.41
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS One (2015) 1.40
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One (2012) 1.38
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
Targeted radiotherapy with gold nanoparticles: current status and future perspectives. Nanomedicine (Lond) (2014) 1.22
The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med (2012) 1.21
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol (2011) 1.20
Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis (2010) 1.17
Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol (2013) 1.16
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm (2010) 1.11
Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye (Lond) (2012) 1.11
Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol (2012) 1.10
Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol (2012) 1.06
Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) (2012) 1.05
Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol (2013) 1.05
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 1.04
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02
Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol (2011) 1.02
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol (2012) 1.01
Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol (2014) 1.01
Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol (2013) 1.00
One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol (2011) 0.99
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Nutritional modulation of age-related macular degeneration. Mol Aspects Med (2012) 0.97
Visual perceptions induced by intravitreous injections of therapeutic agents. Eye (Lond) (2011) 0.97
Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol (2011) 0.97
Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol (2012) 0.97
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond) (2012) 0.96
Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol (2012) 0.95
Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 0.95
Lack of thrombospondin 1 and exacerbation of choroidal neovascularization. Arch Ophthalmol (2012) 0.94
Synthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growth. PLoS One (2014) 0.94
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open (2014) 0.94
[Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe (2015) 0.93
Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 0.93
Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. J Ophthalmol (2016) 0.92
Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci (2013) 0.92
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol (2013) 0.92
Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin Ophthalmol (2011) 0.92
Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.91
Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets. Invest Ophthalmol Vis Sci (2012) 0.90
Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med (2012) 0.89
Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) (2013) 0.89
The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization. Molecules (2014) 0.89
Digital reader vs print media: the role of digital technology in reading accuracy in age-related macular degeneration. Eye (Lond) (2013) 0.88
Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol (2014) 0.88
Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol (2011) 0.88
Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. Arch Ophthalmol (2011) 0.88
Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) (2015) 0.88
Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthalmol (2014) 0.88
Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol (2011) 0.88
Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol (2010) 0.87
Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med (2014) 0.87
Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol (2013) 0.87
Age-Related Macular Degeneration: Advances in Management and Diagnosis. J Clin Med (2015) 0.87
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmol (2015) 0.87
Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol (2015) 0.86
Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol (2013) 0.86
Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes. Graefes Arch Clin Exp Ophthalmol (2014) 0.86
Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization. Redox Biol (2014) 0.86
Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. Clin Ophthalmol (2015) 0.86
Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization. J Med Chem (2015) 0.86
Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients. Graefes Arch Clin Exp Ophthalmol (2012) 0.85
Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) (2015) 0.85
Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration. Retina (2011) 0.85
Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther (2013) 0.85
Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol (2015) 0.85
Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One (2014) 0.85
A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. J Ophthalmol (2014) 0.85
Targeting the IRE1α/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. Am J Pathol (2013) 0.85
Stem cell-based therapies for age-related macular degeneration: current status and prospects. Int J Clin Exp Med (2014) 0.85
Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.84
The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenes Res (2010) 0.84
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol (2014) 0.84
Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. J Ophthalmol (2015) 0.84
Effect of Prior Anti-VEGF Injections on the Risk of Retained Lens Fragments and Endophthalmitis after Cataract Surgery in the Elderly. Ophthalmology (2015) 0.83
Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clin Ophthalmol (2015) 0.83
Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. Int J Ophthalmol (2012) 0.83
Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol (2011) 0.83
Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review. Eye (Lond) (2014) 0.83
Prospectives for gene therapy of retinal degenerations. Curr Genomics (2012) 0.83
Analysis of short-term change in subfoveal choroidal thickness in eyes with age-related macular degeneration using optical coherence tomography. Ophthalmic Surg Lasers Imaging Retina (2014) 0.83
Aflibercept in wet age-related macular degeneration: a perspective review. Ther Adv Chronic Dis (2012) 0.83
Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation. Am J Ophthalmol (2012) 0.83
Role of statins in the development and progression of age-related macular degeneration. Retina (2013) 0.82
Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int (2013) 0.82
Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis. J Ocul Pharmacol Ther (2011) 0.82
Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials. Int J Ophthalmol (2014) 0.82
Retinal pigment epithelium transplantation: concepts, challenges, and future prospects. Eye (Lond) (2015) 0.82
Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol (2014) 0.82
How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration? Eye (Lond) (2014) 0.82
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22
Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol (2003) 4.78
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.09
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology (2009) 3.76
Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina (2008) 2.72
Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina (2013) 2.49
The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology (2013) 2.35
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol (2012) 2.30
Evaluation of wound closure in oblique 23-gauge sutureless sclerotomies with visante optical coherence tomography. Am J Ophthalmol (2008) 2.26
A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology (2006) 2.17
Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome. Retina (2014) 2.15
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol (2013) 2.14
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology (2013) 2.13
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology (2006) 2.07
Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol (2005) 1.99
Intrasurgical dynamics of macular hole surgery: an assessment of surgery-induced ultrastructural alterations with intraoperative optical coherence tomography. Retina (2014) 1.97
Novel microarchitectural dynamics in rhegmatogenous retinal detachments identified with intraoperative optical coherence tomography. Retina (2013) 1.96
Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) (2003) 1.94
Optical coherence tomography enhanced depth imaging of choroidal tumors. Am J Ophthalmol (2011) 1.91
Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol (2008) 1.89
Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol (2013) 1.86
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology (2009) 1.86
Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol (2003) 1.74
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68
Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Am J Ophthalmol (2011) 1.62
Optical coherence tomography 3: Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci (2004) 1.62
Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol (2006) 1.62
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology (2009) 1.52
Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology (2010) 1.49
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Optical coherence tomography of the suprachoroid after CyPass Micro-Stent implantation for the treatment of open-angle glaucoma. Br J Ophthalmol (2013) 1.46
Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology (2007) 1.45
Prevalence of outer retinal tubulation after anti-VEGF therapy for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina (2015) 1.42
Surgeon Willingness to Participate in Randomized Controlled Trials for the Treatment of Femoroacetabular Impingement. Arthroscopy (2015) 1.39
Neovascular age-related macular degeneration: potential therapies. Drugs (2008) 1.38
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005) 1.38
Activity Level and Severity of Dysplasia Predict Age at Bernese Periacetabular Osteotomy for Symptomatic Hip Dysplasia. J Bone Joint Surg Am (2016) 1.38
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 1.37
Descriptive epidemiology of femoroacetabular impingement: a North American cohort of patients undergoing surgery. Am J Sports Med (2013) 1.36
Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol (2012) 1.31
Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina (2012) 1.24
Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am (2006) 1.22
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology (2011) 1.18
Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology (2006) 1.17
Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography. Br J Ophthalmol (2012) 1.17
A novel segmentation algorithm for volumetric analysis of macular hole boundaries identified with optical coherence tomography. Invest Ophthalmol Vis Sci (2013) 1.13
Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol (2010) 1.12
A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology (2010) 1.10
Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology (2012) 1.09
Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol (2006) 1.09
Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg (2013) 1.08
Contrast-enhanced intraoperative optical coherence tomography. Br J Ophthalmol (2013) 1.06
Blast eye injuries: a review for first responders. Disaster Med Public Health Prep (2010) 1.06
Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. Br J Ophthalmol (2006) 1.05
Comparison of retinal thickness measurements between three-dimensional and radial scans on spectral-domain optical coherence tomography. Am J Ophthalmol (2009) 1.05
Do plain radiographs correlate with CT for imaging of cam-type femoroacetabular impingement? Clin Orthop Relat Res (2012) 1.03
Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology (2011) 1.02
Reopening of previously closed macular holes after cataract extraction. Am J Ophthalmol (2007) 1.02
VESGEN 2D: automated, user-interactive software for quantification and mapping of angiogenic and lymphangiogenic trees and networks. Anat Rec (Hoboken) (2009) 1.01
Selective laser trabeculoplasty as a replacement for medical therapy in open-angle glaucoma. Am J Ophthalmol (2005) 1.00
Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol (2002) 1.00
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina (2010) 1.00
Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology (2005) 0.98
Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina (2008) 0.98
Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. Br J Ophthalmol (2010) 0.98
Comparing retinal thickness measurements using automated fast macular thickness map versus six-radial line scans with manual measurements. Ophthalmology (2009) 0.98
Evaluation of wound closure using different incision techniques with 23-gauge and 25-gauge microincision vitrectomy systems. Retina (2008) 0.97
Selective inhibition of angiogenesis in small blood vessels and decrease in vessel diameter throughout the vascular tree by triamcinolone acetonide. Invest Ophthalmol Vis Sci (2008) 0.97
3D Spectral domain optical coherence tomography findings in choroidal tumors. Eur J Ophthalmol (2011) 0.96
Emerging treatments for wet age-related macular degeneration. Expert Opin Emerg Drugs (2014) 0.96
Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology (2007) 0.96
Surgical drainage of chronic serous retinal detachment associated with uveitis. Retina (2008) 0.95
Choroidal thickness in macular holes: a case-control study. Ophthalmic Surg Lasers Imaging Retina (2015) 0.95
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2009) 0.94
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. Arch Ophthalmol (2005) 0.94
Oscillation of angiogenesis with vascular dropout in diabetic retinopathy by VESsel GENeration analysis (VESGEN). Invest Ophthalmol Vis Sci (2009) 0.93
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother (2012) 0.92
Appositional suprachoroidal hemorrhage: a case-control study. Am J Ophthalmol (2004) 0.91
Fourier domain optical coherence tomographic and auto-fluorescence findings in indeterminate choroidal melanocytic lesions. Br J Ophthalmol (2009) 0.91
Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am J Ophthalmol (2012) 0.91
Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology (2013) 0.91
Dynamic evaluation of sutureless vitrectomy wounds: an optical coherence tomography and histopathology study. Ophthalmology (2008) 0.90
A novel mutation in the RDS/Peripherin gene causes adult-onset foveomacular dystrophy. Am J Ophthalmol (2003) 0.90
Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol (2012) 0.90
Scleral thickness following fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm (2010) 0.90
Ranibizumab for age-related macular degeneration. Expert Opin Biol Ther (2012) 0.87
Actinobacillus actinomycetemcomitans endogenous endophthalmitis: report of two cases and review of the literature. Scand J Infect Dis (2003) 0.87